A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

• PUI CH, EVANS WE: Acute lymphoblastic leukemia. N. Engl. J. Med. (1998) 339(9):605-615.
   PubMed Web of Science ®Google Scholar
• JEMAL A, MURRAY T, WARD E et al.: Cancer statistics, 2005. CA Cancer J. Clin. (2005) 55(1):10-30.
   PubMed Web of Science ®Google Scholar
• PISANI P, BRAY F, PARKIN DM: Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer (2002) 97(1):72-81.
   PubMed Web of Science ®Google Scholar
• NOWELL PC, HUNGERFORD DA: A minute chromosome in human chronic granulocytic leukemia. Science (1960) 132:1497.
   Web of Science ®Google Scholar
• ROWLEY JD: Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 243(5405):290-293.
   PubMed Web of Science ®Google Scholar
• PUI CH, RELLING MV, DOWNING JR: Acute lymphoblastic leukemia. N. Engl. J. Med. (2004) 350(15):1535-1548.
   PubMed Web of Science ®Google Scholar
• KURZROCK R, KANTARJIAN HM, DRUKER BJ, TALPAZ M: Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann. Intern. Med. (2003) 138(10):819-830.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN HM, TALPAZ M, DHINGRA K et al.: Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood (1991) 78(9):2411-2418.
   PubMed Web of Science ®Google Scholar
• PRETI HA, O'BRIEN S, GIRALT S, BERAN M, PIERCE S, KANTARJIAN HM: Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am. J. Med. (1994) 97(1):60-65.
   PubMed Web of Science ®Google Scholar
• GOTZ G, WEH HJ, WALTER TA et al.: Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann. Hematol. (1992) 64(2):97-100.
   PubMed Web of Science ®Google Scholar
• MAURER J, JANSSEN JW, THIEL E et al.: Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet (1991) 337(8749):1055-1058.
   PubMed Web of Science ®Google Scholar
• PUI CH: Acute lymphoblastic leukemia. In: Williams Hematology (6th Edition). Beutler E, Coller BS, Lichtman MA, Kipps TJ, Seligsohn U (Eds), McGraw Hill Professional, New York (2001):1141-1161.
   Google Scholar
• BERG SL, STEUBER P, POPLACK DG: Clinical manisfestations of acute lymphoblastic leukemia. In: Hematology, Basic Principles and Practice (3rd Edition). Hoffman R, Benz EJ Jr, Shattil SJ et al. (Eds), Churchill Livingstone, New York (2000):1070-1078.
   Google Scholar
• PUI CH, EVANS WE: Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. (2006) 354(2):166-178.
   PubMed Web of Science ®Google Scholar
• CORNELISSEN JJ, CARSTON M, KOLLMAN C et al.: Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood (2001) 97(6):1572-1577.
   PubMed Web of Science ®Google Scholar
• HOELZER D, GOKBUGET N, OTTMANN O et al.: Acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program (2002):162-192.
   PubMedGoogle Scholar
• PAOLUCCI G, VECCHI V, FAVRE C et al.: Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study. Haematologica (2001) 86(5):478-484.
   PubMed Web of Science ®Google Scholar
• NYVOLD C, MADSEN HO, RYDER LP et al.: Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood (2002) 99(4):1253-1258.
   PubMed Web of Science ®Google Scholar
• RAHIALA J, RIIKONEN P, KEKALAINEN L, PERKKIO M: Cost analysis of the treatment of acute childhood lymphocytic leukaemia according to Nordic protocols. Acta Paediatr. (2000) 89(4):482-487.
   PubMed Web of Science ®Google Scholar
• ISHII E, EGUCHI H, MATSUZAKI A et al.: Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors. Med. Pediatr. Oncol. (2001) 37(1):10-19.
   PubMedGoogle Scholar
• MATSUZAKI A, ISHII E, NAGATOSHI Y et al.: Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi children's cancer study group. Int. J. Hematol. (2001) 73(3):369-377.
   PubMed Web of Science ®Google Scholar
• BLOOMFIELD CD, SECKER-WALKER LM, GOLDMAN AI et al.: Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia. Cancer Genet. Cytogenet. (1989) 40(2):171-185.
   PubMed Web of Science ®Google Scholar
• WESTBROOK CA, HOOBERMAN AL, SPINO C et al.: Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a cancer and leukemia group B study (8762). Blood (1992) 80(12):2983-2990.
   PubMed Web of Science ®Google Scholar
• LARSON RA, DODGE RK, BURNS CP et al.: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study (8811). Blood (1995) 85(8):2025-2037.
   PubMed Web of Science ®Google Scholar
• THOMAS X, THIEBAUT A, OLTEANU N et al.: Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematol. Cell Ther. (1998) 40(3):119-128.
   PubMedGoogle Scholar
• FADERL S, KANTARJIAN HM, THOMAS DA et al.: Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk. Lymphoma (2000) 36(3-4):263-273.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN HM, O'BRIEN S, SMITH TL et al.: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J. Clin. Oncol. (2000) 18(3):547-561.
   PubMed Web of Science ®Google Scholar
• ANNINO L, VEGNA ML, CAMERA A et al.: Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood (2002) 99(3):863-871.
   PubMed Web of Science ®Google Scholar
• RIBERA JM, ORTEGA JJ, ORIOL A et al.: Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica (2002) 87(2):154-166.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI J, KYO T, NAITO K et al.: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia (2002) 16(7):1259-1266.
   PubMed Web of Science ®Google Scholar
• THOMAS X, OLTEANU N, CHARRIN C, LHERITIER V, MAGAUD JP, FIERE D: Acute lymphoblastic leukemia in the elderly: the Edouard Herriot hospital experience. Am. J. Hematol. (2001) 67(2):73-83.
   PubMed Web of Science ®Google Scholar
• ROBAK T: Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches. Drugs Aging (2004) 21(12):779-791.
   PubMed Web of Science ®Google Scholar
• CHAO NJ, BLUME KG, FORMAN SJ, SNYDER DS: Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (1995) 85(11):3353-3354.
   PubMed Web of Science ®Google Scholar
• SNYDER DS, NADEMANEE AP, O'DONNELL MR et al.: Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia (1999) 13(12):2053-2058.
   PubMed Web of Science ®Google Scholar
• GOLDSTONE AH, PRENTICE HG, DURRANT IJ et al.: Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromostome positive (Ph+) acute lymphoblastic leukemia (ALL): results from the International ALL trial (MRC UKALLXII/ECOG E2993). Blood (2001) 98:A856.
   Web of Science ®Google Scholar
• DOMBRET H, GABERT J, BOIRON JM et al.: Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia – results of the prospective multicenter LALA-94 trial. Blood (2002) 100(7):2357-2366.
   PubMed Web of Science ®Google Scholar
• BARRETT AJ, HOROWITZ MM, ASH RC et al.: Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (1992) 79(11):3067-3070.
   PubMed Web of Science ®Google Scholar
• THOMAS DA, FADERL S, CORTES J et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2004) 103(12):4396-4407.
   PubMed Web of Science ®Google Scholar
• THOMAS DA, FADERL S, CORTES J et al.: Update of the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Proceedings of the 46th Annual Meeting of the American Society of Hematology. San Diego, USA (4 – 7 December 2004):2738.
   Google Scholar
• RIBERA JM, ORIOL A, GONZALEZ M et al.: Treatment of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) with concurrent chemotherapy and imatinib mesylate. Proceedings of the 46th Annual Meeting of the American Society of Hematology, San Diego, USA (4 – 7 December 2004):4483.
   Google Scholar
• TOWATARI M, YANADA M, USUI N et al.: Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood (2004) 104(12):3507-3512.
   PubMed Web of Science ®Google Scholar
• YANADA M, TAKEUCHI J, SUGIURA I et al.: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a Phase II study by the Japan adult leukemia study group. J. Clin. Oncol. (2006) 24(3):460-466.
   PubMed Web of Science ®Google Scholar
• LEE S, KIM YJ, MIN CK et al.: The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (2005) 105(9):3449-3457.
   PubMed Web of Science ®Google Scholar
• LEE KH, LEE JH, CHOI SJ et al.: Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia (2005) 19(9):1509-1516.
   PubMed Web of Science ®Google Scholar
• DE LABARTHE A, ROUSSELOT P, HUGUET-RIGAL F et al.: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood (2007) 109(4):1408-1413.
   PubMed Web of Science ®Google Scholar
• DELANNOY A, LHERITIER V, THOMAS X et al.: Treatment of Philadelphia-positive acute lymphocytic leukemia (Ph+ ALL) in the elderly with imatinib mesylate (STI571) and chemotherapy. An interim analysis of the GRAALL AFR09 trial. Proceedings of the 46th Annual Meeting of the American Society of Hematology. San Diego, USA (4 – 7 December 2004):2742.
   Google Scholar
• WASSMANN B, PFIEFER H, GOEKBUGET N et al.: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood (2006) 108(5):1469-1477.
   PubMed Web of Science ®Google Scholar
• HOELZER D, GOKBUGET N: Recent approaches in acute lymphoblastic leukemia in adults. Crit. Rev. Oncol. Hematol. (2000) 36(1):49-58.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344(14):1038-1042.
   PubMed Web of Science ®Google Scholar
• OTTMANN OG, DRUKER BJ, SAWYERS CL et al.: A Phase II study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood (2002) 100(6):1965-1971.
   PubMed Web of Science ®Google Scholar
• OTTMANN OG, WASSMANN B, GOEKBUGET N et al.: A randomized Phase II study comparing imatinib with chemotherapy as induction therapy in elderly patients with newly diagnosed Philadelphia-positive acute lymphoid leukemias (PH+ALL). Hematol. J. (2004) 5:S112.
   PubMedGoogle Scholar
• VIGNETTI M, FAZI P, CIMINO G et al.: Imatinib plus steroids induces complete remission and prolonged survival in elderly Philadelphia chromosome positive acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood (2007) 109(9):3676-3678.
   PubMed Web of Science ®Google Scholar
• WASSMANN B, PFEIFER H, SCHEURING UJ et al.: Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. Blood (2004) 103(4):1495-1498.
   PubMed Web of Science ®Google Scholar
• SHIMONI A, KROGER N, ZANDER AR et al.: Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia (2003) 17(2):290-297.
   PubMed Web of Science ®Google Scholar
• SAVANI BN, SRINIVASAN R, ESPINOZA-DELGADO I et al.: Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. Lancet Oncol. (2005) 6(10):809-812.
   PubMed Web of Science ®Google Scholar
• ARICO M, VALSECCHI MG, CAMITTA B et al.: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N. Engl. J. Med. (2000) 342(14):998-1006.
   PubMed Web of Science ®Google Scholar
• CHAMPAGNE MA, CAPDEVILLE R, KRAILO M et al.: Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a children's oncology group Phase I study. Blood (2004) 104(9):2655-2660.
   PubMed Web of Science ®Google Scholar
• TOKARSKI JS, NEWITT JA, CHANG CY et al.: The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. (2006) 66(11):5790-5797.
   PubMed Web of Science ®Google Scholar
• FENG W, TRAN KT, STEPHENS JM, BOTTEMAN MF: Cost effectiveness of adding imatinib to chemotherapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: an exploratory analysis. Proceedings of the 11th Congress of the European Hematology Association, Amsterdam, The Netherlands (21 – 24 June 2006):805.
   Google Scholar
• DURAND-ZALESKI I: Fixed price contracts: the case of pediatric acute lymphoblastic leukemia. Health Policy (1992) 21(1):65-76.
   PubMed Web of Science ®Google Scholar
• TRAN KT, STEPHENS JM, BOTTEMAN MF, FENG W, HAY JW: Economic and quality of life burden of high-risk acute lymphoblastic leukemia. Proceedings of the 11th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Philadelphia, USA (20 – 24 May 2006):#PHM2.
   Google Scholar
• BLOOM BS, KNORR RS, EVANS AE: The epidemiology of disease expenses. The costs of caring for children with cancer. JAMA (1985) 253(16):2393-2397.
   PubMed Web of Science ®Google Scholar
• BARANKO PV: A cost comparison of laboratory charges in treating childhood leukemia. A children's cancer group analysis. Am. J. Pediatr. Hematol. Oncol. (1994) 16(2):102-103.
   PubMedGoogle Scholar
• YALMAN N, SARPER N, DEVECIOGLU O et al.: Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Turk. J. Pediatr. (2000) 42(3):198-204.
   PubMed Web of Science ®Google Scholar
• REED SD, ANSTROM KJ, LUDMER JA, GLENDENNING GA, SCHULMAN KA: Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer (2004) 101:2574-2583.
   PubMed Web of Science ®Google Scholar
• EARLE CC, CHAPMAN RH, BAKER CS et al.: Systematic overview of cost-utility assessment in oncology. J. Clin. Oncol. (2000) 18(18):3302-3317.
   PubMed Web of Science ®Google Scholar
• CROTT R, ALI F, BURDETTE-RADOUX S: Cost-utility of adjuvant high-dose interferon α therapy in stage III cutaneous melanoma in Quebec. Value Health (2004) 7(4):423-432.
   PubMed Web of Science ®Google Scholar
• MILLER AR, CANTOR SB, PEOPLES GE, PEARLSTONE DB, SKIBBER JM: Quality of life and cost effectiveness analysis of therapy for locally recurrent rectal cancer. Dis. Colon. Rectum (2000) 43(12):1695-1701.
   PubMed Web of Science ®Google Scholar
• WABER DP, SHAPIRO BL, CARPENTIERI SC et al.: Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber cancer institute consortium protocol 87-01. Cancer (2001) 92(1):15-22.
   PubMed Web of Science ®Google Scholar
• EXTERMANN M: Acute leukemia in the elderly. Clin. Geriatr. Med. (1997) 13(2):227-244.
   PubMed Web of Science ®Google Scholar

Websites

• http://seer.cancer.gov/csr/1975_2002 RIES LAG, EISNER MP, KOSARY CL et al. (Eds): SEER Cancer Statistics Review, 1975 – 2002 (2005).
   Google Scholar
• http://seer.cancer.gov/csr/1973_1999 RIES LAG, EISNER MP, KOSARY CL et al. (Eds): SEER Cancer Statistics Review, 1973 – 1999 (2002).
   Google Scholar